Strong Push for Korean Medicine Development: National Institute’s Supported Stroke Recurrence Prevention Herbal Medicine Achieves Export Success in U.S.

Active Support for Overseas Expansion of Outstanding Korean Medicine Products

The herbal medicine Kyunghee Cheonghyeoldan, developed with support from the National Institute for Korean Medicine Development’s “Support Project for Overseas Expansion of Korean Medicine Products,” has entered the U.S. market, marking a significant step toward the globalization of Korean medicine.

National Institute for Korean Medicine Development.

Kyunghee Cheonghyeoldan, a herbal medicine for stroke recurrence prevention, has been researched and developed at Kyung Hee University Korean Medicine Hospital for 20 years and has demonstrated outstanding effectiveness in preventing stroke recurrence in patients.

According to clinical trials that tracked 400 first-time stroke patients at Kyung Hee University Korean Medicine Hospital over two years, 17 patients in the group taking only conventional medicine experienced a second stroke, while only 3 patients in the group taking both conventional medicine and Kyunghee Cheonghyeoldan had a recurrence.

Furthermore, even after five years, only 12 patients in the group taking both conventional medicine and Cheonghyeoldan experienced a recurrence.

Kyunghee Cheonghyeoldan developed by Panacura. Provided by the National Institute for Korean Medicine Development

These results scientifically demonstrate not only that the probability of stroke recurrence was significantly lower for patients who took Kyunghee Cheonghyeoldan together with conventional medicine, but also that Kyunghee Cheonghyeoldan is a highly effective treatment for stroke prevention.

Panacura, which participated in the National Institute for Korean Medicine Development’s “Support Project for Overseas Expansion of Korean Medicine Products,” is the company that developed Kyunghee Cheonghyeoldan. As a company specializing in the development of new natural drugs based on Korean medicine, Panacura has worked to commercialize Kyunghee Cheonghyeoldan through technological cooperation with Kyung Hee University Korean Medicine Hospital.

Kyunghee Cheonghyeoldan completed U.S. customs clearance in early December this year and signed a supply contract with local company Medical-K Inc. Sales will initially begin at pharmacies in the Los Angeles area, and starting in January next year, full-scale marketing will be launched through Radio Korea, the largest Korean-language broadcaster in North America, further accelerating sales efforts.

An official from the National Institute for Korean Medicine Development stated, “The clinical trial results of Kyunghee Cheonghyeoldan are an important case that demonstrates the scientific efficacy of Korean medicine,” adding, “Based on this achievement, we will further accelerate the globalization of Korean medicine and do our utmost to promote Korea’s outstanding traditional medicine to people around the world.”

This content was produced with the assistance of AI translation services.